Treatment of moderate-to-severe plaque psoriasis with tildrakizumab in the real-life setting

Article Page

Abstract

Background: Tildrakizumab is a high-affinity, humanized IgG1κ monoclonal antibody targeting the p19 subunit of IL-23, which is a key regulatory cytokine in psoriasis. Based on evidence from clinical trials, tildrakizumab is approved for the treatment of moderate-to-severe plaque psoriasis in patients eligible for systemic therapy.

Methods: We report our clinical experience with 26 patients followed up to 24 weeks.

Results: No adverse event was observed and no patient discontinued tildrakizumab. Whilst no patient had a Psoriasis Area and Severity Index (PASI) score of <5 at baseline, at week 4, 8 (32%) patients had a PASI score of <3 and 6 of these had a PASI score of 0. At week 12, 19 (79%) patients had a PASI score of <5 and, among these, 18 had a PASI score of <3 of whom 16 had a PASI score of 0. At week 24, 22 (96%) patients had a PASI score of <3 and 20 (87%) had a PASI score of 0. Quality of life was improved after 4 weeks and through the whole period of observation.

Conclusion: Our experience in the real-life setting confirms the efficacy and safety of tildrakizumab as demonstrated by clinical trials.

Keywords: plaque psoriasis, Psoriasis Area and Severity Index, real life, tildrakizumab.

Citation: Burlando M, Castelli R, Cozzani E, Parodi A. Treatment of moderate-to-severe plaque psoriasis with tildrakizumab in the real-life setting. Drugs in Context 2021; 10: 2021-2-6. DOI: 10.7573/dic.2021-2-6

Contributions: All authors contributed to patient care, data collection, manuscript revision and approval. All authors contributed equally to the preparation of this review. All named authors meet the International Committee of Medical Journal Editors (ICMJE) criteria for authorship for this article, take responsibility for the integrity of the work as a whole and have given their approval for this version to be published.

Disclosure and potential conflicts of interest: MB has acted as a speaker and consultant for AbbVie, Janssen, Amgen, Novartis, Eli Lilly, UCB Pharma. AP has served as consultant/investigator for AbbVie, Eli Lilly, Janssen-Cilag, Novartis and UCB Pharma. RC and EC have no conflicts of interest. The International Committee of Medical Journal Editors (ICMJE) Potential Conflicts of Interests form for the authors is available for download at: https://www.drugsincontext.com/wp-content/uploads/2021/04/dic.2021-2-6-COI.pdf

Acknowledgements: Editorial assistance was provided by Laura Brogelli, PhD, and Aashni Shah (Polistudium, Italy), and this activity was funded by Almirall.

Funding declaration: Almirall funded editorial assistance to manuscript preparation.

Copyright: Copyright © 2021 Burlando M, Castelli R, Cozzani E, Parodi A. Published by Drugs in Context under Creative Commons License Deed CC BY NC ND 4.0 which allows anyone to copy, distribute and transmit the article provided it is properly attributed in the manner specified below. No commercial use without permission.

Correct attribution: Copyright © 2021 Burlando M, Castelli R, Cozzani E, Parodi A. https://doi.org/10.7573/dic.2021-2-6. Published by Drugs in Context under Creative Commons License Deed CC BY NC ND 4.0.

Article URL: https://www.drugsincontext.com/treatment-of-moderate-to-severe-plaque-psoriasis-with-tildrakizumab-in-the-real-life-setting

Correspondence: Martina Burlando, Largo Rosanna Benzi X, 16132, Genova, Italy. Email: martina.burlando@unige.it

Provenance: Submitted; externally peer reviewed.

Submitted: 25 February 2021; Accepted: 22 April 2021; Publication date: 21 May 2021.

Drugs in Context is published by BioExcel Publishing Ltd. Registered office: Plaza Building, Lee High Road, London, England, SE13 5PT.

BioExcel Publishing Limited is registered in England Number 10038393. VAT GB 252 7720 07.

For all manuscript and submissions enquiries, contact the Editorial office editorial@drugsincontext.com

For all permissions, rights and reprints, contact David Hughes david.hughes@bioexcelpublishing.com

Download free full text PDF